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Abstract: Due to safety concerns in recent years, much effort has been devoted to improving 
the outcomes associated with drug-eluting stents (DESs). This review summarizes the current 
status of methodological and technical achievements reported in second-generation DES. Novel 
stents are described based on the component (the platform, the polymer, and the drug) that has 
undergone the most significant changes compared to earlier generation DES. An overview of 
the currently available evidence on the use of novel coronary devices in patients undergoing 
coronary revascularization is also reviewed.
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Introduction
The introduction of first-generation drug-eluting stents (DESs) in the setting of per-
cutaneous coronary intervention (PCI) has led to a significant decrease in the need for 
repeat revascularization, a common limitation associated with the use of bare-metal 
stents (BMS). In-stent restenosis, the result of a maladaptive neointimal tissue prolif-
eration, is dramatically reduced by the long-lasting inhibitory effect exerted by the 
local elution of antiproliferative agents.1–3
First-generation DES commonly consist of three elements: an antiproliferative 
drug, a durable polymer that serves for drug loading and modification of release   kinetics, 
and the stent platform (Figure 1). The first generation of DES employs a cobalt–
chromium alloy, a durable polymer, and elutes sirolimus (Cypher; Cordis, Warren, NJ) 
or paclitaxel (TAxuS™; Boston Scientific, Natick, MA). Sirolimus- and paclitaxel-
eluting stents seem to provide similar rates of revascularization, although several 
studies report a more profound inhibition of neointimal hyperplasia by sirolimus.4–6 
While other first-generation DES have been produced,7 the second-generation DES 
now include the zotarolimus- (Endeavor; Medtronic, Minneapolis, MN) and the everoli-
mus- (xience V; Abbott Vascular, Redwood City, CA) eluting stents.8,9
Despite the higher efficacy compared to BMS, concerns remain regarding the 
long-term safety of DES, including localized hypersensitivity and late stent 
thrombosis.10–12 Although the exact mechanisms of these pathological reactions have 
not yet been fully elucidated, they seem to be most likely associated with the presence 
of durable polymers, representing a trigger for inflammation and subsequent impaired 
re-endothelialization.13 In previous years, several efforts have been devoted by research-
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possible advancements of platform, carrier, and pharmaco-
logical technologies, and many innovations have been pro-
vided aiming at improving biocompatibility and long-term 
outcomes of patients undergoing PCI.
This review summarizes the current status of method-
ological and technical achievements reported in second-
generation DES, giving an account of the most recent clinical 
data and the latest improvements in treatment of de novo 
coronary lesions. For the purpose of the following discus-
sion, novel stents will be described based on the component 
(the platform, the polymer, and the drug) that has undergone 
the most significant changes compared to earlier generation 
DES (Figure 2). We searched Medline to identify studies 
which assessed second-generation DES, using search terms 
such as ‘novel stents’, ‘second-generation drug eluting 
stent’, ‘stent polymer’, and ‘biodegradable stents’. In addi-
tion, we identified relevant abstracts and presentations at the 
annual meetings of the American Heart Association, the 
American College of Cardiology, the European Society of 
Cardiology, the European Association of Percutaneous 
Coronary Intervention, Transcatheter Cardiovascular Thera-
peutics, and Transcatheter Cardiovascular Therapeutics Asia 
Pacific from July to September 2010. Expert slide presenta-
tions were consulted online from tctmd.com to complete 
data from abstracts. Internet-based sources of information 
on the results for clinical trials in cardiology (see http://
www.   theheart.org and http://www.tctmd.com) were also 
searched.
Innovations in stent platforms
Recent innovations in stent platforms include changes of the 
metallic alloy (ie, shifting from cobalt–chromium or stainless 
steel to platinum–chromium platforms) or development of 
dedicated stent platforms for the treatment of specific subsets 
of lesions (ie, bifurcations and small-vessel lesions).
Changes of the metallic alloy
Element™ Stent Platform
The Element Stent Platform (Boston Scientific) is made up 
 of a platinum–chromium alloy. The platinum–chromium 
platform has a new stent architecture with a thin strut thick-
ness (81 µm), which features high radiopacity, high radial 
strength, and conformability. The Element Stent Series 
includes an everolimus-eluting (PROMuS Element™;   Boston 
Scientific) and a paclitaxel-eluting stent (TAxuS™ Element; 
Boston Scientific). Both stents have received the Conformité 
Européenne (CE) Mark.
The safety and effectiveness of the PROMuS Element 
stent for the treatment of de novo atherosclerotic coronary 
lesions are the object of the ongoing prospective, randomized, 
multicenter PLATINuM (Clinical Trial to Assess the 
  PROMuS Element Stent System for Treatment of De Novo 
Coronary Artery Lesions) trial (Clinicaltrials.gov identifier 
NCT00823212). In the prospective, randomized PERSEuS 
(Prospective Evaluation in a Randomized Trial of the 
Safety and Efficacy of the use of the TAxuS Element 
Paclitaxel-Eluting Coronary Stent System) Workhorse trial 
(NCT00484315), the TAxuS Element has proven to be 
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Figure 1 Schematic representation of the structure of a conventional DES.
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Figure 2 Diagram of topics and stents described in this review.
Abbreviations: AMS, absorbable-metal stent; BVS, bioresorbable vascular scaffold; 
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noninferior to the first-generation TAxuS Express with 
regard to the incidence of 12-month target lesion failure 
(TLF) (5.6% vs 6.1% for TAxuS Element and TAxuS 
Express, respectively, P = 0.78) for the treatment of de novo 
atherosclerotic lesions of up to 28 mm in length in native 
coronary arteries of 2.75–4.0 mm diameter. In addition, there 
were no differences in terms of in-stent late loss between the two 
stents (0.34 ± 0.55 vs 0.26 ± 0.52 mm, P = 0.33) at 9-month 
follow-up.14 Conversely, the TAxuS PERSEuS Small 
  Vessel trial (NCT00489541) is a prospective, multicenter, 
single-arm superiority trial, currently ongoing, which aims 
to assess the safety and efficacy of the TAxuS Element stent 
for the treatment of de novo atherosclerotic lesions #20 mm 
in length in native coronary arteries of $2.25 to ,2.75 mm 
diameter.
Dedicated bifurcation stents
The dedicated stents have been developed with the goal of 
addressing some of the most common issues associated with 
PCI of a bifurcation lesion, including difficulties in maintain-
ing side-branch access throughout the procedure, main vessel 
stent struts jailing the side-branch ostium, distortion of main 
vessel stent after side-branch dilatation, and failure to cover 
and scaffold the side-branch ostium.15 First-generation 
bifurcation-dedicated BMS include the Multi-Link   Frontier™ 
(Guidant Corp, Santa Clara, CA),16 the SLK-View™ (Advanced 
Stent Technologies, Pleasanton, CA),17 the Petal™ (Advanced 
Stent Technologies),18 the Sideguard™ (Cappella Inc, Galway, 
Ireland),19,20 the Twin-Rail™ (Invatec Srl, Roncadelle, Italy),21 
the Nile Croco™ (Minvasys, Genevilliers, France),22 the 
Tryton™ (Tryton Medical Inc, Durham, NC),23 the Sidekick™ 
(Y-med Inc, San Diego, CA),24 and the Antares SAS™ (Tri-
Reme Medical Inc, Pleasanton, CA).25 These stents lack a 
drug-eluting coating and are associated with a high rate of 
restenosis ranging between 28% and 54%.26 A new generation 
of bifurcation-dedicated DES is currently under clinical inves-
tigation and will be discussed in the following paragraphs.
Axxess Plus™
The Axxess (Devax Inc, Irvine, CA) stent is a self-expanding 
nickel–titanium alloy stent featuring a conical configuration 
designed to conform with the bifurcation anatomy, which 
provides easy access to the distal branches for easy place-
ment of subsequent stents (Figure 3). The stent is coated   
with a resorbable polymer which elutes Biolimus A9.   
The Axxess Plus regis  try reported low in-stent late loss   
(0.09 ± 0.56 mm) and rest  enosis (4.8%) with the Axxess stent 
at 6 months follow-up.27 The DIVERGE (Drug-Eluting Stent 
Intervention for Treating Side Branches Effectively) study 
(n = 302) showed encouragingly low major adverse cardiac 
events (MACEs) (7.7%) and target lesion revascularization 
(TLR) rates (4.3%) at 9 months follow-up.28 The randomized 
COBRA (COmplex BifuRcation Lesions: A Comparison 
Between the AxxESS Device and Culotte Stenting: An 
Optical Coherence Tomography) study (NCT00895791) will 
enroll 40 patients and assess vessel healing at 9 months by 
optical coherence tomography (OCT) in bifurcation lesions 
treated using the Axxess stent or the culotte technique. This 
stent has received the CE Mark in July 2010.
TAXUS Petal™ stent
The TAxuS Petal (Boston Scientific) dedicated stent is the 
improved version of the AST Petal stent, acquired by Boston 
Scientific in 2004. Its platinum–chromium platform is stron-
ger and more radiopaque than a stainless steel platform with 
four radiopaque markers for good visualization on angiog-
raphy and includes a main branch section with a side-branch 
opening to provide mechanical scaffolding and drug delivery 
to the side-branch ostium. The TAxuS Petal stent is coated 
with the same poly(styrene-b-isobutylene-b-styrene) polymer 
as the TAxuS Express and the TAxuS Libertè stents and 
releases paclitaxel in the same manner. The first-in-man study 
of the TAxuS Petal stent reported a composite rate of all 
death, myocardial infarction (MI), or target vessel revascu-
larization (TVR) of 3.7% and 14.8% at 30-day and 12-month 
follow-up, respectively, 6-month in-segment late loss of 
0.47 ± 0.45 and 0.41 ± 0.57 mm for the proximal and distal 
main branch, respectively, and 0.18 ± 0.39 mm for the side 
branch.29
Figure 3 Representation of the self-expanding nickel-titanium Axxess stent in its 
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Nile Pax™
The Nile Pax (Minvasys) dedicated stent is a chromium–
cobalt stent, with a 73-µm strut thickness and a modular 
design, developed using the Pax technology, previously 
utilized in the Amazonia Pax stent. Similar to this latter stent, 
the Nile Pax is characterized by a polymer-free paclitaxel 
abluminal coating to avoid long-term lack of endothelization 
and to deliver the drug exclusively onto the arterial wall. 
Paclitaxel is applied using a microdrop spray crystallization 
process. The stent has a dedicated bifurcation delivery system 
made of specific balloon catheters.30 The safety and efficacy 
of this novel stent is currently evaluated in the prospective, 
nonrandomized, single-arm multicenter BIPAx (dedicated 
bifurcation with the PAx technology) trial on 102 patients. 
Preliminary results have demonstrated good results for the 
treatment of de novo bifurcation lesions including high acute 
success (99%), neither cardiac death nor stent thrombosis at 
30 days clinical follow-up and absence of thrombotic events 
after hospital discharge.31
STENTYS™
The STENTYS (Stentys S.A.S., Paris, France) dedicated 
stent is a provisional, self-expanding nitinol stent developed 
both as a DES and as a BMS. The main peculiarity of this 
stent is the possibility of creating a side-branch access any-
where in the stent after implantation in the main vessel. The 
side-branch opening is created by inflating the angioplasty 
balloon into the mesh, thus, disconnecting the interconnections. 
The drug-eluting form elutes paclitaxel (dose: 0.8 µg/mm2) 
which is loaded in a blend of a durable polymer of polysulfone 
and polyvinyl-pyrrolidone. In the first-in-man trial of 
40 patients, the stent showed a 95.5% procedural success rate, 
which is defined as technical and angiographic success in 
the absence of any MACE at hospital discharge. Disconnection 
of the strut to create the side-branch opening was successfully 
achieved in 95% of patients. After stent implantation in the 
main branch, stenting the side branch was necessary in one-
third of the cases.32 In the prospective, nonrandomized, 
multicenter APPOSITION I study (n = 25), the in-stent late 
loss was 0.71 ± 0.70 mm and the rate of angiographic rest-
enosis (.50%) was 25% at 6 months; no cases of death, 
stent thrombosis, or MI were noted at the same follow-up.33 
In the randomized, multicenter APPOSITION II study 
(NCT01008085), 80 patients with ST-elevation myocardial 
infarction (STEMI) were randomized to the STENTYS stent 
versus a conventional balloon-expandable stent and followed 
up with OCT for 3 days. Preliminary data reported a significant 
reduction in stent strut malapposition with the STENTYS 
stent (0.51% vs 5.33%, P , 0.001).34 This stent has received 
the CE Mark in May 2010.
Lesions in small vessels
A small vessel diameter is still an independent predictor 
of angiographic and clinical restenosis. DES have been 
employed for the treatment of lesions located in the small 
vessels, but their impact on clinical and angiographic outcomes 
is not yet well established. It can be expected that DES 
implantation could bring a reduction in restenosis and the 
need for repeat revascularization, as shown in several studies, 
but large, randomized studies are necessary to elucidate the 
safety and efficacy of both traditional and next-generation 
DES in this scenario.35,36
Cardiomind Sparrow™
The Cardiomind Sparrow (Biosensors, Morges, Switzerland) 
stent is a self-expanding nitinol stent loaded into a 0.014″-
guidewire platform, which is developed to treat lesions in 
small vessels. It has a closed cell design and an ultrathin 
strut (0.0024″). The stent is deployed through a proprietary 
mechanism, which enables the electrolysis of mechanical 
latches at each end of the device. This process is initiated 
and controlled by electrical energy delivered from a handheld 
battery.37
Two versions of the Cardiomind Sparrow stent have 
been developed. The first version was a BMS assessed in the 
prospective, multicenter, feasibility CARE I study that 
enrolled 22 patients and reported a rate of MACE of 9.5% 
at 24-month follow-up and an in-stent late lumen loss of 
0.73 ± 0.57 mm at 6-month follow-up.38 The second version is 
a DES with a strut thickness of 67 µm (compared to 140 µm of 
Cypher stent and 132 µm of TAxuS stent) in which the anti-
proliferative agent sirolimus is combined in the SynBiosys™ 
polylactic acid (PLA) biodegradable copolymer matrix. 
The dose of the drug is ∼6 µg/mm. This second-generation 
stent was compared to the BMS version tested in the CARE 
I study and traditional BMS in the prospective, multicenter, 
multinational three-arm randomized CARE-II study. The 
trial showed an in-stent late lumen loss of 0.29 ± 0.45 mm 
in the sirolimus-eluting stent arm versus 0.86 ± 0.54 of 
bare metal Cardiomind and 0.99 ± 0.45 mm of BMS at 
8-month follow-up; the rates of binary restenosis were 
6.7%, 45.2%, and 44.0%, respectively, and the rates of 
cumulative MACE were 6.25%, 8.6%, and 16.7% at the same 
follow-up.39,40Vascular Health and Risk Management 2011:7 submit your manuscript | www.dovepress.com
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Conclusions
The innovations in stent platform discussed in this section 
anticipate promising results, in particular for the treatment 
of challenging lesions, such as long lesions, bifurcations 
lesions, and those located in small vessels, but larger studies 
with adequate follow-up are needed to evaluate the safety of 
novel metal alloys and modified stent designs.
Innovations in polymers
Stents with durable polymers
Endeavour Resolute™
The Endeavour Resolute (Medtronic CardioVascular Inc, 
Santa Rosa, CA) is a next-generation zotarolimus-eluting 
stent developed by Medtronic to improve the clinical out-
comes associated with the first-generation Endeavor stent. 
It is comprised of a Driver cobalt–chromium stent platform, 
similar to the Endeavor stent, the antiproliferative agent 
zotarolimus, and, instead of the Endeavor stent’s phospho-
rylcholine polymer, a new biocompatible polymer called 
BioLinx™.41 This polymer is a blend of three different 
  polymers, a hydrophobic C10 polymer, a hydrophilic C19 
polymer, and a hydrophilic polyvinyl-pyrrolidinone, designed 
to provide a robust coating and to enhance polymer biocom-
patibility, reducing the risk of delayed healing and late stent 
thrombosis. The polymer also extends the duration of drug 
exposure in the vessel, such that ∼50% of the zotarolimus is 
released within the first week, with the remaining drug 
released beyond 31 days.42
The stent’s clinical effectiveness and safety have been 
evaluated in 139 patients enrolled in the prospective, multi-
center, nonrandomized, single-arm, controlled first-in-man 
RESOLuTE trial, which showed a late lumen loss of 
0.22 ± 0.27 mm and an in-stent binary restenosis of 1.0% at 
9 months angiographic follow-up.41 The cumulative rates of 
MACE, TLR, and target vessel failure (TVF) reported at 2-year 
follow-up were 10.1%, 1.4%, and 7.9%, respectively.43
Recently, the Endeavour Resolute stent has been compared 
to the xience™ V everolimus-eluting stent in the prospective, 
multicenter, randomized, two-arm, international, noninferiority 
RESOLuTE-III all-comers trial (NCT00617084), in which 
2300 patients were enrolled. The results of this study showed 
the Resolute to be noninferior to xience V for the primary 
endpoint of composite TLF (cardiac death, target vessel MI, 
or clinically driven TLR) at 12 months follow-up (Resolute 
8.2% vs xience V 8.3%, Pnoninferiority , 0.001).44
The Endeavour Resolute stent has received the CE Mark 
in 2007.
Excella™ stent
This stent is described in the Innovations in drugs – New drugs 
section.
Stents with biodegradable polymers
Sirolimus-based
Supralimus™
The Supralimus stent (Matrix; Sahajanand Medical Technolo-
gies, Surat, Gujarat, India) is a stainless steel stent with a two-
layer biodegradable polymer coating. The base layer is a mix of 
poly-l-lactic acid (PLLA), poly-lactide-co-  glycolide, and 
polyvinyl-pyrrolidone, which releases 50% of sirolimus 
within the first week and the remaining 50% in the next 41 days. 
The surface polyvinyl-pyrrolidone layer has a protective func-
tion and degrades completely within 2 h after implantation.
In the prospective, nonrandomized, first-in-man SERIES I 
study, 100 patients were treated with the Supralimus stent. Data 
showed a 6% rate of MACE at 9 months follow-up and an 
event-free survival rate of 93% at 30 months. The rates of 
6-month in-stent and in-segment restenosis in a prespecified 
subgroup of 60 patients were 0% and 1.7%, respectively; the 
in-stent and in-segment late loss were 0.09 ± 0.28 and 0.02 ± 
0.37 mm, respectively, at the same angiographic follow-up.45
The safety and efficacy of the Supralimus stent in the 
treatment of unselected patients with acute coronary syn-
drome undergoing PCI have been evaluated in the pro-
spective, multicenter E-SERIES registry which showed 
acceptable rates of MACE, TLR, and stent definite and prob-
able thrombosis of 10.0%, 2.7%, and 0.6%, respectively, at 
12 months follow-up.46
Further data will be produced by the prospective, mul-
ticenter, randomized, noninferiority SERIES III trial 
(NCT00917163), which is currently ongoing. This study 
includes a head-to-head comparison with the xience V stent 
for the primary endpoint of in-stent luminal late loss at 
9 months after stent implantation.
Excel™
The Excel stent (JW Medical Co Ltd, Shandong Province, 
Weihai, China) is composed of the S-Stent’s (Biosensor 
International) stainless steel laser-cut platform, which confers 
a high flexibility, a very thin coating (10–15 µm) of sirolimus, 
and a PLA biodegradable polymer, which can be expected 
to have a complete degradation within 6–9 months. The Excel 
stent has been investigated in the CREATE (Multi-Center 
Registry Trial of ExCEL Biodegradable Polymer Drug-
Eluting Stent, NCT00331578) registry in 2077 patients. Vascular Health and Risk Management 2011:7 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
108
Capodanno et al
The predefined primary endpoint was the incidence of 
MACE (cardiac death, nonfatal MI, and TLR) at 12 months 
follow-up after stent implantation. The trial reported MACE 
rates of 2.7% and 3.1% at 12- and 18-month follow-up, 
respectively, and an angiographic in-stent late lumen loss of 
0.21 ± 0.39 mm.47 In this study, 80.5% of patients discontin-
ued clopidogrel treatment within 6 months, given the use of 
a biodegradable polymer. The rate of stent thrombosis proved 
to be 0.87% at 18 months of follow-up.
NEVO™
The NEVO stent (Cordis) is made up of a cobalt–chromium 
alloy platform, with open cell design to improve vessel 
conformability. It is the first DES applying the Cordis RES 
Technology™, which consists of hundreds of reservoirs 
embedded in the struts, each acting as a depot loaded with a 
drug–polymer mix. The active ingredient in the drug–
polymer composition is sirolimus, with similar drug dose 
and release kinetics as Cypher. The polymer loaded into 
reservoirs is a poly-lactic acid-co-glycolic acid (PLGA). 
Polymer’s degradation time can be controlled by altering the 
lactide/glycolide ratio, and specifically for NEVO stent, 
PLGA completes bioabsorption in a very short duration of 
90 days. This technology offers several advantages, first a 
higher drug/polymer ratio and thus both higher drug dose 
and lower polymer mass than conventional DES. Moreover, 
reservoirs coat a small percentage of stent surface, which is 
therefore for the most part bare metal, in contrast to other 
DESs that are totally polymer coated. This feature conceivably 
increases stent vessel biocompatibility.48
In the randomized, multicenter, single-blind NEVO 
RES-I (Comparison of the Conor Sirolimus-eluting Coronary 
Stent to the TAxuS Liberté Paclitaxel-eluting Coronary Stent 
in the Treatment of Coronary Artery Lesions, NCT00606333) 
trial, the NEVO stent was compared to the TAxuS Liberté 
paclitaxel-eluting coronary stent in 394 patients. NEVO was 
associated with significantly lower in-stent late lumen loss 
(0.13 vs 0.36 mm, P , 0.001) at 6-month quantitative coro-
nary angiography (QCA) follow-up.49 In addition, NEVO 
showed lower rates of death (0.5% vs 2.2%), MI (2.0% vs 
3.2%), MACE (6.1% vs 10.8%), and TLR (3.6% vs 5.9%) 
than TAxuS at 12 months follow-up. No cases of stent 
thrombosis occurred at the same follow-up in the NEVO 
group in contrast with two late thromboses (one possible and 
one probable) in the TAxuS group.50 Further studies have 
been designed to investigate the NEVO stent, such as the 
ongoing prospective, multicenter NEVO RES-II study 
(NCT00714883). The NEVO II trial (NCT01202058) will 
be a randomized, noninferiority trial comparing the NEVO 
stent to the xience everolimus-eluting coronary stent with 
the aim of assessing clinical outcomes during 5 years of 
follow-up. The prospective CYNERGY (Cynergy: the 
CYPHER-NEVO Registry) study (NCT01106378) is recruit-
ing participants to assess the noninferiority of NEVO, once 
commercially available, to CYPHER in patients with acute 
STEMI, diabetes mellitus, or multivessel disease.
Biolimus-based
The BioMatrix Flex stent and the Nobori stent, both coated 
with a biodegradable polymer, are described in the Innova-
tions in drug – New drugs section.
Paclitaxel-based
Infinnium™
The biodegradable polymers, which coat the stainless steel 
balloon-expandable platform of the Infinnium stent (Matrix; 
Sahajanand Medical Technologies) are poly-l-lactide, poly-
dl-lactide-co-glycolide, poly-l-lactide-co-caprolactone, and 
polyvinyl-pyrrolidone. These polymers are stratified in 
composition with the antiproliferative agent paclitaxel, each 
layer with a different drug release kinetics. Infinnium stent’s 
safety and efficacy have been assessed in 103 patients 
enrolled in the multicenter, prospective, nonrandomized 
SIMPLE II study, which aimed at investigating the incidence 
of MACE (primary endpoint) at 30 days and in-stent binary 
restenosis by QCA at 6 months follow-up. Results showed 
rates of MACE at 30 days, 6 months, and 9 months to be 
2.9%, 4.9%, and 9.7%, respectively. Data from QCA indi-
cated in-stent and in-segment binary restenosis rates of 7.3% 
and 8.3% associated with in-stent and in-segment late loss 
of 0.38 ± 0.49 and 0.18 ± 0.46 mm, respectively.51
The Infinnium stent has been compared with the above-
mentioned Supralimus stent and a BMS control in the ran-
domized, multicenter PAINT trial (NCT00752362), which 
reported a significant reduction in late loss and TVR at 
9 months follow-up for DES (both Infinnium 0.54–0.44 mm 
and Supralimus 0.32–0.43 mm) compared with BMS 
(0.90–0.45 mm).52 This stent has received the CE Mark.
JACTAX™
The JACTAx™ (Boston Scientific) Liberté is made up of a 
premounted stainless steel platform coated with a polymer-
drug blend of a low molecular weight biodegradable poly-
lactide polymer and paclitaxel. This process, known as 
Juxtaposed Abluminal Coating technology, applies minimal 
amount of polymer-drug composition in discrete areas Vascular Health and Risk Management 2011:7 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
109
Novel drug-eluting stents
(2750 microdots/16 mm stent) exclusively located onto the 
abluminal surface, such that the other three sides of the stent 
remain BMS surface. Polymer thickness is #1 µm, approxi-
mately 15 times thinner than that of the TAxuS Liberté stent 
polymer. The drug paclitaxel is fully released in 60 days, 
while the polymer degrades within 4 months.
The prospective, single-center, randomized OCTDESI 
(Optical Coherence Tomography Drug Eluting Stent Inves-
tigation) trial (NCT00776204) was designed to evaluate the 
long-term proportion of strut coverage and the vessel wall 
response with the JACTAx stent at 6 months, with either 
low drug dose (LD) or high drug dose (HD), compared to 
the TAxuS Libertè stent. Data showed that the primary 
endpoint of the percentage of uncovered stent struts per 
patient at 6 months follow-up measured by OCT was similar 
for the three devices (5.3% ± 14.7% for TAxuS Liberté, 
7.0% ± 12.2% for JACTAx HD, and 4.6% ± 7.3% for 
  JACTAx LD; P = 0.81).53,54 There were no deaths, Q wave MIs, 
or stent thromboses at 12-month clinical follow-up.
An evaluation of safety and clinical performance of the 
JACTAx HD stent have been performed in a prospective, multi-
center, nonrandomized first-in-man study (NCT00754728), 
which recruited 103 patients who had underwent PCI with 
the aforementioned stent compared to an historical control 
group of patients treated with the TAxuS Liberté stent from 
the ATLAS trial.55 Results in patients treated with JACTAx 
HD stent showed that the primary endpoint of MACE (cardiac 
death, MI, and ischemia-related TVR) occurred at 9 months 
in 7.8% of patients, a value significantly below the 17% 
noninferiority limit, thus meeting the prespecified criteria 
for noninferiority to the TAxuS Liberté stent. Moreover, 
there was no death, Q wave MI, or stent thrombosis during 
follow-up. Results of QCA demonstrated an in-stent late loss 
of 0.33 ± 0.45 mm and an in-stent binary restenosis of 5.2%, 
which are comparable values to those observed in similar-
matched patients from the TAxuS ATLAS trial. Mean net 
volume obstruction by intravascular ultrasound (IVuS) was 
11.4% ± 11.2%.56 The JACTAx LD stent has been assessed 
in the prospective, multicenter, randomized JACTAx LD 
Drug Eluting Stent Trial (NCT00754975) and completed in 
August 2010. This trial randomized 130 patients from the 
JACTAx LD stent or the TAxuS Libertè. The study results 
are awaited.
CoStar™
The CoStar stent (Conor MedSystems, Menlo Park, CA) is 
a cobalt–chromium stent that elutes paclitaxel without the 
use of a surface polymer using holes located on the surface 
of the stent, each one acting as a reservoir for a drug-polymer 
blend. The polymer loaded into the reservoirs is a bioresorb-
able PLGA polymer, which degrades mediating drug delivery 
such that at the end of biodegradation process, only the bare-
metal platform remains. The CoStar stent was first evaluated 
in several study (PISCES and COSTAR I ed EuroStar) and 
showed satisfactory results.57–59 However, in the multicenter, 
single-blind, two-arm, randomized, controlled, noninferiority 
trial COSTAR II study (NCT00165035) (n = 1700), the 
CoStar stent was not demonstrated to be noninferior in clinical 
and angiographic performance compared with the paclitaxel-
eluting TAxuS stent: the MACE rate was 11.0% for Costar 
and 6.9% for TAxuS (P , 0.005) at 8-month follow-up, 
and the in-segment late loss was 0.49 mm for CoStar and 
0.18 mm for Taxus (P , 0.0001).60 The CoStar stent has 
received the CE Mark.
Nonpolymeric stent
YUKON®
A microporous stainless steel platform forms the basis of 
the completely polymer-free YuKON stent (Translumina, 
Hechingen, Germany), which has been combined with 
rapamycin using a technology denominated ISAR (Individu-
alised Drug-Eluting Stent System to Abrogate Restenosis). 
This technology consists of a two-component system, a mobile 
stent-coating device for the spraying process of the drug and 
a disposable stent cartridge holding the premounted stainless 
steel microporous stent. The ISAR process allows to coat the 
platform with various drugs directly on-site customizing the 
drug dose. During the coating process, as soon as the two 
components are correctly located, the drug is sprayed on the 
stent surface, and it is subsequently dried by removing the 
ethanol with pressured air. The entire process takes ∼8 min.61 
According to previous studies, ISAR stents are safe and effec-
tive with a 2% rapamycin-coating solution.62 The microporous 
surface has the function of drug reservoir and retards drug 
release, consequently the polymer serves no function.
In the randomized ISAR-TEST, in which a total of 
450 patients were enrolled, the YuKON stent has been 
compared to the polymer-based, paclitaxel-eluting TAxuS 
stent for the treatment of de novo coronary lesions, with the 
aim of assessing the noninferiority of the rapamycin-eluting 
stent. The results of the study demonstrated that the YuKON 
stent is noninferior to the TAxuS stent with regards to the 
incidence of angiographic and clinical restenosis.63 In the 
prospective, randomized ISAR-TEST-3 (Rapamycin-Eluting 
Stents With Different Polymer Coating to Reduce Restenosis), 
the Yukon DES was compared to a rapamycin-eluting stent Vascular Health and Risk Management 2011:7 submit your manuscript | www.dovepress.com
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with biodegradable polymer and to a rapamycin-eluting   
stent with permanent polymer (Cypher) in 605 patients. The 
study was completed in 2007 and reported a 6- to 8-month 
in-stent late loss of 0.47 mm for the YuKON stent compared 
with 0.17 mm for the rapamycin-eluting stent with biodegrad-
able polymer and 0.23 mm for Cypher, showing low efficacy 
for the polymer-free YuKON stent.64
The safety of the YuKON stent has also been evaluated 
in a real-world registry (n = 410), in which a group of patients 
treated with YuKON stent was compared to a group of those 
who had undergone PCI with TAxuS stent. This study 
showed no statistically significant differences in terms of 
MACE at 6 months follow-up between the two groups of 
patients; specifically, one MI occurred in the TAxuS stent 
group and no case in the YuKON stent group (0.2% vs 0%, 
respectively), and 15 TLR (7.3%) were performed in the 
YuKON stent group versus 7 in the TAxuS stent group 
(3.4%).65 A prospective, observational study weighed the 
difference in in-stent late lumen loss between 6–8 months 
and 2 years in patients treated with permanent-polymer 
DES Cypher or TAxuS or with polymer-free rapamycin-
eluting stents. Angiographic data obtained after 2-year 
  follow-up indicate that the absence of permanent polymer 
from DES has a protective function against delayed in-stent 
late lumen loss (YuKON stent 0.01 ± 0.42 mm, Cypher stent 
0.17 ± 0.50 mm, and TAxuS stent 0.13 ± 0.50 mm; 
P , 0.001).66 This stent has received the CE Mark and is 
available for sale in Europe.
BioFreedom™
The BioFreedom (Biosensors) stent is a stainless steel 
polymer-free stent, currently under development and releas-
ing Biolimus A9™, a rapamycin derivate with immuno-
suppressive and antiproliferative properties which has already 
been used on the BioMatrix, Nobori, xtent, and DEVAx 
stents. In the first cohort of the prospective, multicenter, 
randomized, single-blinded BioFreedom FIM Clinical Trial 
(NCT01172119), the stent was compared to the TAxuS 
Libertè stent in two-drug dosage versions, namely a standard-
dose version (SD, 15.6 µg/mm of stent length) and a LD 
version (7.8 µg/mm of stent length). The 4-month follow-up 
results reported in the first cohort (n = 74) showed a signifi-
cant reduction (P , 0.0001) of in-stent late loss in both the 
  BioFreedom SD and LD groups (0.08 and 0.12 mm, respec-
tively), compared to the TAxuS Libertè group (0.37 mm). 
In addition, no cases of stent thrombosis were noticed in 
the study during 4 months. The 12-month angiographic 
follow-up of the second cohort (n = 107) demonstrated the 
noninferiority of the BioFreedom SD compared to TAxuS 
stent with regard to in-stent late loss (0.17 vs 0.35 mm, 
respectively; P = 0.001) and a trend toward superiority 
(P = 0.11). The rates of MACE at the same follow-up were 
6.1% for BioFreedom SD, 11.6% for BioFreedom LD, and 
5.5% for TAxuS stent in all patients (first and second 
cohorts), with no case of stent thrombosis.67 In a recent study, 
the BioFreedom stent showed equivalent early and superior 
late reduction of neointimal proliferation compared with 
the polymer-coated sirolimus-eluting Cypher stent in a 
  porcine model.68
Amazonia Pax®
The Amazonia Pax stent (Minvasys) is made up of a polymer-
free chromium–cobalt alloy platform, with open cell design, 
eluting the antiproliferative agent paclitaxel. The drug layer 
(thickness: 5 µm) is applied using a microdrop spray crystal-
lization process, exclusively onto the abluminal surface, and 
is loaded with a paclitaxel dose of 2.5 µg/mm2. The stent is 
designed to release ∼98% of the drug in 30 days, returning 
to regular chromium–cobalt after 45 days. Strut and coating 
thicknesses are 73 and 5 µm, respectively, ensuring a total 
stent thickness of 78 µm, less than that found on other stents 
(Cypher stent: 152.6 µm and TAxuS stent: 148 µm). Clinical 
evaluation of the Amazonia Pax stent is currently ongoing 
in the prospective, randomized, multicenter-active controlled, 
single-blinded PAx A trial and in the prospective, nonran-
domized PAx B trial. The 4 months follow-up results of the 
PAx A trial, in which the Amazonia Pax stent was compared 
with the TAxuS stent, showed in-stent late lumen loss of 
0.77 and 0.42 mm (P = 0.20), respectively, and a percentage 
of stent obstruction by IVuS of 19% and 6% (P = 0.08), 
respectively, revealing no significant difference between these 
two  stents  in  angiography  and  IVuS  quantitative 
parameters.69,70 Minvasys has received the CE Mark for 
Amazonia Pax stent in 2010.
VESTAsync™
In the VESTAsync-eluting stent (MIV Therapeutics, 
Atlanta, GA), a polymer-free stainless steel platform is 
incorporated with a nanothin-microporous hydroxyapatite 
surface coating impregnated with a low-dose lipid-sirolimus 
mixture. The hydroxyapatite coating dissolves completely 
after 9–12 months, while the elution of sirolimus is complete 
within 3 months. The stent has been evaluated in the prospec-
tive, nonrandomized, single-center VESTASYNC I FIM 
clinical trial in 15 patients. Data have confirmed the sustained 
efficacy of this polymer-free stent showing a lumen late Vascular Health and Risk Management 2011:7 submit your manuscript | www.dovepress.com
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loss of 0.36 ± 0.23 mm by QCA analysis and an in-stent 
  percentage volume obstruction by IVuS of 4.0 ± 2.2 mm3 at 
9 months follow-up. Long-term clinical follow-up reported 
no MACE (cardiac/noncardiac death, cerebrovascular 
  accident, nonfatal MI, and stent thrombosis) at 12 months 
follow-up and only a case of TLR at 36 months follow-up.71 
In the randomized VESTASYNC II study (n = 120), the 
VESTAsync sirolimus-eluting stent was compared with a 
control BMS. The 8-month QCA analysis showed an in-stent 
late lumen loss of 0.39 ± 0.20 mm for VestaSync stent com-
pared with 0.74 ± 0.52 on the control BMS (P = 0.03).72
Conclusions
The polymer is one of the main DES elements in charge of 
hypersensitivity and late stent thrombosis after implantation. 
Therefore, innovations in this component, as showed by the 
early results of some devices of this category already used 
in daily practice, are likely to exert a positive influence on 
PCI outcomes in the near future.
Innovations in drugs
Drugs combination system
SymBio™
A new solution in developing DES consists of loading a stent 
with more drugs. This technology has been used in the 
  SymBio stent (Conor Medsystems). This stent includes the 
Conor reservoirs technology, already used in the Costar stent, 
which provides the capability to load drug in hundreds of 
small holes, each acting as a drug-polymer reservoir, and to 
control the delivery time and rate. In the SymBio stent, 
in contrast to the Costar stent loaded with paclitaxel, two 
drugs, specifically paclitaxel and pimecrolimus, are loaded 
in adjacent reservoirs. Pimecrolimus is an anti-inflammatory 
agent with immunosuppressant properties used for the topical 
treatment of atopic dermatitis.
Despite the combination of two drugs in a unique stent, 
in the randomized, multicenter GENESIS (Randomized, 
MultiCenter Study of the Pimecrolimus-Eluting and 
  Pimecrolimus/Paclitaxel-Eluting Coronary Stent Systems) 
trial (NCT00322569), which compared the paclitaxel-eluting 
Costar stent, the pimecrolimus-eluting Corio™ stent, and the 
dual-combination drugs SymBio stent by Conor Medsystem, 
data failed to demonstrate either SymBio or Corio angio-
graphic noninferiority when compared with paclitaxel-
eluting stent. The in-stent late loss values at 12 months 
follow-up were 0.58 ± 0.58 mm for the Costar stent, 
1.40 ± 0.67 mm for the Corio stent, and 0.96 ± 0.73 mm for 
the SymBio stent (P , 0.001).73
New drugs
Novolimus
Excella™
The Excella novolimus-eluting stent (Elixir Medical, 
Sunnyvale, CA) is a next-generation DES, which consists 
of a cobalt–chromium platform with a strut thickness of 
0.0032″ and eight-crown design for optimal scaffolding, 
a biocompatible methacrylate polymer with a coating thick-
ness of ,3 µm (compared with 7.6 µm for everolimus-eluting 
stents), and a new ‘limus’ family-related drug called novolimus. 
This drug is a macrocyclic lactone, metabolite of sirolimus, 
which demonstrates high potency to inhibit neointimal 
  proliferation. This feature results in a drug dose of 5 µg/mm, 
lower than that found in other stents like zotarolimus- or 
everolimus-eluting stents (10 µg/mm). Both lower drug dose 
and polymer load seem to confer to the stent significant safety 
and efficacy.
The results from the first-in-man ExCELLA I study, 
which recruited 15 patients, showed an in-stent late loss of 
0.31 ± 0.25 mm and a neointimal volume of 6.0% ± 4.4% 
by IVuS at 8 months follow-up.74 Recently, the randomized 
ExCELLA II (Elixir Medical Clinical Evaluation of the 
Novolimus-Eluting Coronary Stent System: a Randomized 
Study With a Single-Arm Registry) study (NCT00792753) 
demonstrated an angiographic lumen late loss of 0.11 ± 0.32 mm 
and a neointimal volume obstruction of 20.9% ± 11.3%.75
Biolimus
BioMatrix™ Flex
The BioMatrix Flex biolimus-eluting stent (Biosensors) 
incorporates a stainless steel stent platform with a strut 
thickness of 112 µm and an abluminal PLA biodegradable 
polymer. The PLA polymer completely degrades into carbon 
dioxide and water within 6–9 months. In the randomized 
LEADERS (Trial Limus Eluted from A Durable Versus 
ERodable Stent Coating) trial (NCT00389220) (n = 1707), 
the BioMatrix stent has been compared to the Cypher 
sirolimus-eluting stent with a noninferiority study design. 
At 12 months, the BioMatrix stent was noninferior to Cypher 
stent for MACE (10.6% and 12.0%, respectively; P = 0.37).76 
The BioMatrix stent noninferiority to Cypher stent has been 
ratified at 2 years follow-up with similar outcomes.77 
Recently, the safety and efficacy of the BioMatrix stent have 
also been demonstrated in a single-center trial. This study 
reported an in-stent late loss of 0.24 ± 0.39 mm for the 
BioMatrix group and 0.71 ± 0.47 mm for the control group 
(S-Stent, P , 0.001).78 The BioMatrix stent has received the 
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Nobori™
The Nobori stent (Terumo Corporation, Tokyo, Japan) elutes 
Biolimus A9 and consists of the stainless steel S-stent and a 
biodegradable PLA polymer, similar to that of the BioMatrix 
stent, except for the delivery system and the stent coating 
process. For the nonrandomized, multicenter Nobori Core 
study, 107 patients were recruited to demonstrate the similar-
ity between the Nobori stent and Cypher stent. It reported an 
in-stent late loss of 0.10 ± 0.26 and 0.13 ± 0.44 mm 
(P = 0.66), respectively, at 9 months angiographic follow-up, 
thus confirming the predefined hypothesis of similarity 
between the two stents.79 The randomized Nobori 1 trial 
(n = 243) demonstrated the noninferiority of the Nobori stent 
versus TAxuS Libertè stent for the primary endpoint of 
angiographic in-stent late loss at 9 months postprocedure 
(Nobori 0.11 ± 0.30 mm and TAxuS Libertè 0.32 ± 0.50 mm; 
P = 0.001). In addition, in both stents, the rate of MACE was 
low, and no cases of stent thrombosis occurred at the same 
follow-up.80 The Nobori stent has the potential to reduce throm-
botic events, promoting a complete endothelial   regeneration.81 
Further and more extensive evaluations of this stent are 
awaited in the coming years. In particular, for a multicenter, 
randomized study (NCT01186120), ∼500 patients are being 
recruited to compare the Nobori stent with the PROMuS 
Element stent for long coronary lesions. A randomized trial 
(NCT01097434), currently enrolling participants (estimated 
enrollment, 45 patients), will evaluate the superiority of the 
Nobori stent versus the xience V stent with regard to the abso-
lute percentage of uncovered stent strut segments. The prospec-
tive, randomized ISAR-TEST 6 trial (NCT01068106) will 
compare the efficacy and the safety of the Nobori stent with 
that of the xience V stent. The Nobori stent has received the 
CE Mark.
Myolimus
Myolimus™ Eluting Coronary system
Myolimus is a macrocyclic lactone, sirolimus analogous, 
used in the Myolimus™ Eluting Coronary system (Elixir 
Medical) in composition with three proprietary polymer 
technologies: a durable polymer, a biodegradable polymer 
developed to biodegrade within 6 months, and a biodegrad-
able polymer which biodegrades within 9 months. The results 
of the single-arm, multicenter, first-in-man study on the Elixir 
Myolimus-eluting stent with a durable polymer show an in-
stent late loss of 0.15 ± 0.11 mm at angiographic analysis 
and a neointimal volume of 1.4% ± 1.2% at IVuS at 6 months 
follow-up.82
Clinical data obtained from a single-arm, multicenter, 
first-in-man study on the Myolimus-eluting stent with bioab-
sorbable polymers indicate a late lumen loss of 0.13 ± 0.27 mm 
at angiographic analysis and a neointimal volume of 
5.4% ± 8.4% at IVuS at 12 months of follow-up.83
Conclusions
The combination of new drugs, as the biolimus, with other 
innovative DES components, as biodegradable polymers, 
has already provided good results, and it is an established 
fact in the landscape of interventional cardiology.
Biodegradable stents
In spite of so many improvements in the development of DES, 
there are still many concerns regarding the neointimal prolifera-
tion and the risk of late stent thrombosis by using this technol-
ogy. These complications have been attributed to the presence 
of uncovered metal struts in direct contact with blood and to 
the possibility of incomplete vessel healing. So far, DES have 
been modified in their components, namely drug, polymer, and 
platform, by the several aforementioned solutions with the aim 
of averting the complications of coronary angioplasty.
In contrast to older devices, biodegradable stents represent 
a new concept of coronary stent. The need for vessel scaffolding 
is transitory, so a permanent stent is unnecessary after the vessel 
has healed. Biodegradable stents completely degrade after 
implantation and, causing the disappearance of any foreign 
material exposed to blood if endothelialization is delayed or 
incomplete, they may hypothetically reduce the risk for late 
stent thrombosis. Moreover, biodegradable stents may have 
other potential advantages, such as promoting reconstitution 
of local vascular compliance, avoiding covering of side-branch, 
facilitating the use of lesion imaging with multislice computed 
tomography, angiography, or cardiac magnetic resonance, and 
allowing further surgical or percutaneous treatments to the same 
lesion.84,85 Biodegradable stents were first implanted in 1980s 
with good results, but none has received either the CE Mark or 
united States Food and Drug Administration approval. Further 
ameliorations and large-scale randomized trials with long-term 
follow-up are necessary to enhance and evaluate the safety and 
efficacy of this technology.
Poly-l-lactide stents
Bioresorbable Vascular Scaffold™
The Bioresorbable everolimus-eluting Vascular Scaffold 
(BVS; Abbott Vascular) is made up of a backbone of 
PLLA coated with a thin layer of poly-d,l-lactide (PDLLA) Vascular Health and Risk Management 2011:7 submit your manuscript | www.dovepress.com
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and elutes everolimus. PLLA is a fully biodegradable 
  semicrystalline polymer, which forms a conglomeration of 
crystalline and amorphous phases when it solidifies. The 
structure and the state of this polymer change in relation to 
temperature and deformation history. PDLLA is a biodegrad-
able polymer coating PLLA, which forms, similar to the 
PLLA, an amorphous phase when it solidifies at room and 
physiological temperatures. The PDLLA allows controlled 
release of the drug such that ∼80% of everolimus is eluted 
within 28 days. The absorption process of PLLA and PDLLA 
occurs via hydrolysis, producing lactic acid, and subsequently 
degrades via the Krebs cycle, and small particles ,2 µm in 
diameter are phagocytosed by macrophages. With regard to 
preclinical trials, it seems that complete absorption of the stent 
could occur within 2–3 years after implantation (Figure 4).
Two versions of the stent have been developed. The design 
of the BVS stent Revision 1.0 consists of circumferential 
out-of-phase zigzag hoops of PLLA with a strut thickness of 
150 µm, linked either directly or by straight bridges, with two 
radiopaque markers at each end which enable a good visual-
ization on angiography. It has been evaluated in 30 patients 
in the cohort A of the prospective, open-labeled, first-in-man 
ABSORB (Bioabsorbable Vascular Solutions First-in-Man 
Clinical Investigation: a Clinical Evaluation of the Bioab-
sorbable Vascular Solutions Everolimus-Eluting Coronary 
Stent System in the Treatment of Patients With Single de Novo 
Native Coronary Artery Lesions) study (NCT00300131).86 
The in-stent late loss reported at 2 years angiographic 
  follow-up did not significantly differ from that found at 
6 months follow-up (0.48 ± 0.28 mm vs 0.43 ± 0.37 mm; 
P = 0.233). The multi-imaging approach (IVuS-virtual 
histology and OCT) at the same follow-up showed that the 
stent was incorporated into the vessel wall and that several 
implanted stents were no longer discernible by OCT.87 
The rate of MACE at 6 months follow-up was 3.3%, and no 
new MACE events occurred between 6 months and 3 years. 
No stent thrombosis or TLR occurred up to 3 years follow-up. 
A significant restoration of vasomotion was reported at the 
same follow-up, but the study showed some limitations. 
In particular, the duration of radial support may be insuffi-
cient to resist the coronary remodeling after PCI, and the 
scaffold shrinkage could cause quite high in-stent late loss 
value reported at 6 months follow-up.88
The BVS Revision 1.1 consists of the same polymer, but 
different process refinements allow the stent to increase its 
radial force, provide radial support for a longer time, and, 
consequently, avoid the slightly higher, but nonsignificant, 
recoil shown by QCA.89–91 This stent version has a different 
strut distribution, reducing the maximum circular unsup-
ported cross-sectional area, in contrast to BVS Revision 1.0.92 
It is currently under evaluation in the Cohort B of the non-
randomized ABSORB trial (NCT00856856) in 80 patients. 
Data reported an in-scaffold late loss of 0.19 mm at 6 months 
angiographic follow-up and a MACE rate of 4.4% (TVF 
4.4%) at 9 months clinical follow-up (one non-Q wave MI 
and one ischemia driven-TLR); no scaffold thrombosis 
occurred over the follow-up.93
REVA™
The scaffolding of the REVA bioabsorbable stent (REVA 
Medical, San Diego, CA) consists of a biodegradable tyrosine 
polycarbonate polymer, which metabolizes to amino acids, 
ethanol, and carbon dioxide. The rate of re-absorption 
depends on molecular weight and can be modified for dif-
ferent utilizations, for example, specific use in vulnerable 
plaques or diabetic lesions. This polymer is also radiopaque 
because of binding iodine molecules directly into the polymer 
backbone. The expansion mechanism of the stent is based 
on the ‘slide and lock design’. This technology enables the 
stent to expand without significant deformation, providing 
high-radial strength compared to stainless stent with negli-
gible recoil (,1%).94 The first-generation stent, which did 
not elute any drug, has been assessed in the prospective, 
multicenter, single-arm, safety, first-in-man RESORB (REVA 
Endovascular Study of a Bioresorbable Coronary Stent)   
study (27 patients enrolled), which showed a higher than 
anticipated rate of TLR at 4–6 months follow-up, most likely 
caused by reduction in stent diameter, even though without 
evidence of shrinkage or negative vessel remodeling.95,96   
The next-generation stent, called the ReZolve™ stent,   
everolimus
PDLLA
PLLA
Scaffold shirnkage
Intimal hyplerplasia
Baseline 6 months 24 months
artery wall
Figure 4 Bioabsorption process of the BVS stent and relative degradation times.
Abbreviations: PDLLA, poly-d,l-lactic acid; PLLA, poly-l-lactic acid; BVS, bioresorbable 
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uses a ‘slide and lock’ mechanism, but it has been optimized 
using a coating of sirolimus, a more robust material, and a 
spiral design to enhance dimensional stability and to maintain 
mechanical integrity under high loading both initially and 
over time. This stent is undergoing clinical evaluation.97
BTI™
A bioabsorbable polymer of salicylic acid, the active ingre-
dient of aspirin with anti-inflammatory and antiplatelet 
properties, constitutes the basis for the BTI stent (Bioab-
sorbable Therapeutics Inc, Menlo Park, CA). The stent has 
two layers composed of salicylic-acid derivates: the core 
provides mechanical scaffolding, while the surface layer 
contains sirolimus that is eluted during the biodegradation 
process together with a dose of salicylic acid of ∼10 µg.98 
The blend of sirolimus and salicylic acid ensures both anti-
proliferative and anti-inflammatory actions. The complete 
absorption of the stent is expected within 6–12 months. 
  Following successful preclinical trials on porcine coronary 
arteries, the multicenter first-in-man WHISPER trial dem-
onstrated acceptable safety and the absence of acute or 
chronic recoil, but on the other hand, data reported an insuf-
ficient neointimal suppression presumably due to the low 
dose and very rapid elution of sirolimus. As a result, the first-
generation stent has been modified by increasing the drug 
dose and slowing down the elution time. Today, this second-
generation stent is under testing in a preclinical trial on 
porcine coronaries.99,100
IGAKI-TAMAI™
The bioabsorbable IGAKI-TAMAI stent (Kyoto Medical 
Planning Co Ltd, Kyoto, Japan) is made up of a monofilament 
of PLLA polymer (thickness: 0.17) with a zigzag design. It 
has two radiopaque gold markers at each end to facilitate 
visualization on angiography. This PLLA stent is both thermal 
self-expanding and balloon expandable; it gets its original 
size in 0.2 sec when heated to 70°C. The stent expansion in 
the implant site by balloon occurs within 30 sec and is per-
formed by balloon inflation of a heated dye at 80°C. After 
the inflation process, the self-dilatation continues progres-
sively until the definitive equilibrium size. The IGAKI-TAMAI 
stent was the first-biodegradable stent implanted in a human. 
The first version of the stent lacked an antiproliferative drug. 
In the first-in-man study, it was evaluated on 15 patients 
treated with 25 stents in 19 lesions. Data reported at 6 months 
indicate a late loss of 0.48 ± 0.32 and no ST or MACE at 
clinical follow-up, but the rates of   angiographic restenosis 
and of TLR per lesion were both 10.5%. IVuS revealed an 
expansion of the stent over the follow-up and the presence 
of stent strut at 6 months; in addition, the mean stent cross-
sectional area was similar at 3 and 6 months (8.18 and 
8.13 mm2; P = 0.30).101
In another study, in which 50 elective patients with 
63 lesions treated with 84 IGAKI-TAMAI stents were 
enrolled, a 10-year follow-up (the longest available follow-up 
of a biodegradable coronary stent) reported rates of cardiac 
and noncardiac death-free survival of 97.8% and 87.0%, 
respectively, a rate of MACE-free survival of 48.4%, and 
a rate of TLR of 23.8%.102,103 Data showed a low complication 
rate, but at present, due to concerns about the use of heat to 
induce self-expansion, no further human coronary implants 
have been carried out, and today, the stent is only available 
in Europe for peripheral use. A version of the stent with a 
coating of paclitaxel has been deployed in porcine coronary 
arteries; the drug coating was shown to effectively inhibit 
proliferation and coronary stenosis after vascular intervention 
in a long-term follow-up.104
Bioabsorbable magnesium stent
One of the problems with the bioabsorbable stent is the above-
mentioned lower radial strength when compared to stainless 
steel traditional devices. Biodegradable metallic stents have 
been developed with the aim of exceeding these limitations; 
in particular, they provide a combination of the advantages of 
a polymeric biodegradable stent, such as the complete degrada-
tion of the implants and a fast recovery of vasomotion, with 
the benefits of stainless steel stents, including an effective 
radial force.
The absorbable-metal stent (AMS; Biotronik, Berlin, 
Germany) is a balloon-expandable stent, laser cut from a tube 
of bioabsorbable alloy which is composed mainly of magne-
sium (.90%). This technology for tube production provides 
a reduced wall thickness. The expected degradation time is 
,56 days.105 Three generations of stent have been designed. 
The first-generation stent (AMS-1), which lacked a drug 
coating, was evaluated in 63 patients in the prospective, 
nonrandomized, multicenter PROGRESS-AMS trial, show-
ing no deaths, nonfatal MIs, or stent thromboses at 4 and 
12 months follow-up. On the other hand, the rate of TLR was 
39.7% and 45% at 4 and 12 months follow-up, respectively, 
and the in-stent late loss was 1.08 ± 0.49 mm at 4 months 
angiographic follow-up.106
A second-generation stent, called AMS-2, was developed 
to improve the results of the AMS-1. It is characterized by 
a slower degradation, a thinner strut thickness, and a modern 
design. In preclinical studies, the AMS-2 demonstrated Vascular Health and Risk Management 2011:7 submit your manuscript | www.dovepress.com
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encouraging results with regard to neointimal proliferation 
and to prolonged stent integrity. After the AMS-2, a further 
version of the stent, called AMS-3, has been developed. 
This version of the stent, which is the first drug-eluting 
absorbable magnesium stent, has already been reported in 
animal trials and showed significant improvement in mini-
mum lumen diameter at 14 and 28 days compared to AMS-1 
and late loss indices comparable to conventional DES.107 
Currently, the nonrandomized first-in-man trial BIOSOLVE-I 
(BIOTRONIKS-Safety and Clinical Performance Of the 
First Drug-Eluting Generation Absorbable Metal Stent In 
Patients With de Novo Lesions in NatiVE Coronary Arteries. 
NCT01168830), which will assess the safety of the AMS-3, 
is recruiting participants.
Conclusions
Recent approaches in development of next-generation DES 
have been reported in this review. In past years, a lot of effort 
has been devoted to improving the safety and efficacy of new 
coronary stents. Some of the above are already available for 
daily practice, while others need further studies to validate 
their use on humans. Larger trials and longer   follow-up are 
necessary to assess the effectiveness of these novel devices, 
but, given that DES will continue to have a prominent part 
in PCI in the near future, the aims so far reached suggest the 
achievement of important results.
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